NASDAQ · OCGN
Healthcare · Biotechnology
$0.95
Down-$0.02 (-2.27%)
Updated Nov 11, 2026, 1:15 PM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OCGN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 10, 2026
OCGN closed at $0.95 after 21 trading sessions, up 7.30% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 10, 2026 | $0.9895 | $1.055 | $0.9228 | $0.95 | 7.29M |
| Nov 9, 2026 | $0.9769 | $0.9942 | $0.925 | $0.9721 | 9.37M |
| Nov 6, 2026 | $0.8301 | $0.9669 | $0.825 | $0.925 | 7.47M |
| Nov 5, 2026 | $0.9099 | $0.9304 | $0.7908 | $0.8165 | 7.15M |
| Nov 4, 2026 | $0.811 | $0.89 | $0.78 | $0.8745 | 8.81M |
| Nov 3, 2026 | $0.745 | $0.7899 | $0.7317 | $0.7452 | 4.98M |
| Nov 2, 2026 | $0.72 | $0.7476 | $0.7036 | $0.7247 | 5.71M |
| Oct 30, 2026 | $0.746 | $0.76 | $0.6909 | $0.7027 | 5.42M |
| Oct 29, 2026 | $0.78 | $0.7964 | $0.7406 | $0.7442 | 5.53M |
| Oct 28, 2026 | $0.7698 | $0.8037 | $0.7466 | $0.7764 | 9.23M |
| Oct 27, 2026 | $0.7225 | $0.78 | $0.7101 | $0.7574 | 8.69M |
| Oct 26, 2026 | $0.7402 | $0.75 | $0.7016 | $0.7084 | 8.31M |
| Oct 23, 2026 | $0.7951 | $0.7951 | $0.732 | $0.7397 | 8.59M |
| Oct 22, 2026 | $0.80 | $0.835 | $0.79 | $0.79 | 6.72M |
| Oct 21, 2026 | $0.8256 | $0.83 | $0.7906 | $0.8151 | 4.32M |
| Oct 20, 2026 | $0.79 | $0.84 | $0.786 | $0.8125 | 6.66M |
| Oct 19, 2026 | $0.8025 | $0.8149 | $0.782 | $0.7873 | 4.47M |
| Oct 16, 2026 | $0.84 | $0.84 | $0.7803 | $0.7803 | 5.15M |
| Oct 15, 2026 | $0.8401 | $0.85 | $0.79 | $0.8137 | 5.94M |
| Oct 14, 2026 | $0.888 | $0.9197 | $0.785 | $0.8412 | 9.53M |
| Oct 13, 2026 | $0.9454 | $0.9454 | $0.87 | $0.8854 | 6.89M |
The latest Smart Investors Daily articles mentioning OCGN.
Company
Market Activity
Research & News
OCGN research
Company profile and research snapshot.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HC Wainwright & Co. | Buy | — |
| May 27, 2026 | Canaccord Genuity | Buy | — |
| Mar 25, 2026 | Chardan Capital | Buy | — |
| Mar 25, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 17, 2026 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Yahoo · Nov 4, 2026
Ocugen Inc (OCGN) advances all three late-stage modifier gene therapy programs into Phase 3 with key data readouts expected in 2027, backed by $84.6 million in cash and new licensing deals.
Yahoo · Nov 4, 2026
Ocugen (NASDAQ:OCGN) said its third-quarter progress centered on advancing three retinal gene therapy programs in late-stage development, expanding regional partnerships and establishing a European presence to support future commercialization efforts. Chairman, Chief Executive Officer and Co-Founde
Yahoo · Nov 4, 2026
Moby summary of Ocugen, Inc.'s Q3 2026 earnings call
SeekingAlpha · Nov 4, 2026
Ocugen, Inc. (OCGN) Q3 2026 Earnings Call November 4, 2026 8:30 AM ESTCompany ParticipantsChris Clark - VP of Corporate CommunicationsShankar Musunuri -...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OCGN.
